FamiCord (V3V.DE) Stock Price

FamiCord Price

XETRA·CLOSED
2.75EUR+0.02 (+0.73 %)
Market closed

Over the last 18 years FamiCord grew revenue by 10.2% annually, reaching 88.17 M EUR. Earnings per share have grown at 4.5% per year over the last 11 years. For FamiCord, the net margin of -7.1% is up versus -13.8% a few years ago. At today's price the dividend yield works out to roughly 5.82%. The payout ratio is around 51% of earnings. The dividend has grown at 1.6% per year over the past 4 years. The consensus 12-month price target for FamiCord is 7.65 EUR, about 178.2% above where the stock trades today. Of 7 analysts, 0 rate the stock a buy — an overall Sell consensus. The stock trades about 3% above its 52-week low.

FamiCord stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of FamiCord over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how FamiCord stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing FamiCord's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

FamiCord Stock Price History
DateFamiCord Price
8/14/20262.75 EUR
8/13/20262.73 EUR
8/12/20262.68 EUR
8/11/20262.80 EUR
8/10/20262.76 EUR
8/7/20262.79 EUR
8/6/20262.90 EUR
8/5/20262.70 EUR
8/4/20262.90 EUR
7/31/20262.90 EUR
7/30/20262.85 EUR
7/29/20262.84 EUR
7/28/20262.90 EUR
7/27/20262.97 EUR
7/24/20262.82 EUR
7/23/20262.96 EUR
7/22/20262.86 EUR
7/21/20262.92 EUR
7/20/20262.91 EUR
7/17/20263.13 EUR
7/16/20263.07 EUR
7/15/20263.17 EUR
7/14/20263.12 EUR
7/13/20263.17 EUR
7/10/20263.28 EUR
7/9/20263.24 EUR
7/8/20263.00 EUR
7/7/20263.32 EUR
7/6/20263.44 EUR
7/3/20263.50 EUR
7/2/20263.63 EUR
7/1/20263.71 EUR
6/30/20263.71 EUR
6/29/20263.77 EUR
6/26/20263.78 EUR
6/25/20263.83 EUR
6/24/20263.83 EUR
6/23/20263.83 EUR
6/22/20263.83 EUR
6/19/20263.81 EUR
6/18/20263.76 EUR
6/17/20263.82 EUR
6/16/20263.77 EUR
6/15/20263.80 EUR
6/12/20263.80 EUR
6/11/20263.82 EUR
6/10/20263.75 EUR
6/9/20263.90 EUR
6/8/20263.94 EUR
6/5/20263.94 EUR
6/4/20263.89 EUR
6/3/20263.91 EUR
6/2/20263.91 EUR
6/1/20263.96 EUR
5/29/20263.97 EUR
5/28/20263.92 EUR
5/27/20263.98 EUR
5/26/20264.01 EUR
5/25/20264.01 EUR
5/22/20263.98 EUR
5/21/20263.98 EUR
5/20/20263.96 EUR
5/19/20263.93 EUR
5/18/20264.04 EUR
5/15/20264.00 EUR
5/14/20263.99 EUR
5/13/20264.00 EUR
5/12/20264.09 EUR
5/11/20264.09 EUR
5/8/20264.11 EUR
5/7/20264.15 EUR
5/6/20264.40 EUR
5/5/20264.38 EUR
5/4/20264.38 EUR
4/30/20264.44 EUR
4/29/20264.50 EUR
4/28/20264.42 EUR
4/27/20264.50 EUR
4/24/20264.53 EUR
4/23/20264.53 EUR
4/22/20264.53 EUR
4/21/20264.51 EUR
4/20/20264.55 EUR
4/17/20264.58 EUR
4/16/20264.58 EUR
4/15/20264.63 EUR
4/14/20264.69 EUR
4/13/20264.69 EUR
4/10/20264.69 EUR
4/9/20264.73 EUR
4/8/20264.75 EUR
4/7/20264.66 EUR
4/2/20264.68 EUR
4/1/20264.72 EUR
3/31/20264.72 EUR
3/30/20264.72 EUR
3/27/20264.72 EUR
3/26/20264.72 EUR
3/25/20264.72 EUR
3/24/20264.78 EUR
3/23/20264.74 EUR
3/20/20264.82 EUR
3/19/20264.82 EUR
3/18/20264.94 EUR
3/17/20264.88 EUR
3/16/20264.96 EUR
3/13/20264.96 EUR
3/12/20264.98 EUR
3/11/20264.98 EUR
3/10/20264.88 EUR
3/9/20264.78 EUR
3/6/20265.00 EUR
3/5/20265.05 EUR
3/4/20265.05 EUR
3/3/20265.00 EUR
3/2/20265.10 EUR
2/27/20265.20 EUR
2/26/20265.20 EUR
2/25/20265.20 EUR
2/24/20265.20 EUR
2/23/20265.20 EUR
2/20/20265.30 EUR
2/19/20265.25 EUR
2/18/20265.15 EUR
2/17/20265.30 EUR
2/16/20265.25 EUR
2/13/20265.30 EUR
2/12/20265.35 EUR
2/11/20265.30 EUR
2/10/20265.30 EUR
2/9/20265.30 EUR
2/6/20265.30 EUR
2/5/20265.30 EUR
2/4/20265.25 EUR
2/3/20265.25 EUR
2/2/20265.30 EUR
1/30/20265.35 EUR
1/29/20265.30 EUR
1/28/20265.25 EUR
1/27/20265.25 EUR
1/26/20265.60 EUR
1/23/20265.60 EUR
1/22/20265.65 EUR
1/21/20265.75 EUR
1/20/20265.85 EUR
1/19/20265.80 EUR
1/16/20265.75 EUR
1/15/20265.85 EUR
1/14/20265.85 EUR
1/13/20266.00 EUR
1/12/20266.00 EUR
1/9/20266.00 EUR
1/8/20265.95 EUR
1/7/20265.95 EUR
1/6/20265.95 EUR
1/5/20265.85 EUR
1/2/20266.05 EUR
12/30/20256.00 EUR
12/29/20256.10 EUR
12/23/20256.10 EUR
12/22/20256.00 EUR
12/19/20256.00 EUR
12/18/20256.85 EUR
12/17/20256.85 EUR
12/16/20256.85 EUR
12/15/20256.85 EUR
12/12/20256.85 EUR
12/11/20255.90 EUR
12/10/20255.65 EUR
12/9/20255.40 EUR
12/8/20255.40 EUR
12/5/20255.40 EUR
12/4/20255.40 EUR
12/3/20255.30 EUR
12/2/20255.35 EUR
12/1/20255.40 EUR
11/28/20255.25 EUR
11/27/20255.20 EUR
11/26/20255.20 EUR
11/25/20255.25 EUR
11/24/20255.35 EUR
11/21/20255.30 EUR
11/20/20255.30 EUR
11/19/20255.35 EUR
11/18/20255.30 EUR
11/17/20255.25 EUR
11/14/20255.30 EUR
11/13/20255.35 EUR
11/12/20255.35 EUR
11/11/20255.35 EUR
11/10/20255.45 EUR
11/7/20255.40 EUR
11/6/20255.40 EUR
11/5/20255.20 EUR
11/4/20255.30 EUR
11/3/20255.30 EUR
10/31/20255.30 EUR
10/30/20255.40 EUR
10/29/20255.40 EUR
10/28/20255.45 EUR
10/27/20255.35 EUR
10/24/20255.65 EUR
10/23/20255.80 EUR
10/22/20255.75 EUR
10/21/20255.85 EUR
10/20/20255.85 EUR
10/17/20255.95 EUR
10/16/20255.95 EUR
10/15/20255.95 EUR
10/14/20256.05 EUR
10/13/20256.00 EUR
10/10/20256.05 EUR
10/9/20255.80 EUR
10/8/20255.80 EUR
10/7/20255.70 EUR
10/6/20255.90 EUR
10/3/20255.90 EUR
10/2/20255.95 EUR
10/1/20255.75 EUR
9/30/20255.80 EUR
9/29/20255.80 EUR
9/26/20255.75 EUR
9/25/20255.60 EUR
9/24/20255.65 EUR
9/23/20255.85 EUR
9/22/20256.25 EUR
9/19/20256.25 EUR
9/18/20256.35 EUR
9/17/20256.50 EUR
9/16/20256.50 EUR
9/15/20256.55 EUR
9/12/20256.30 EUR
9/11/20256.65 EUR
9/10/20256.90 EUR
9/9/20256.90 EUR
9/8/20256.90 EUR
9/5/20256.95 EUR
9/4/20256.85 EUR
9/3/20256.80 EUR
9/2/20256.80 EUR
9/1/20257.15 EUR
8/29/20257.40 EUR
8/28/20257.40 EUR
8/27/20257.25 EUR
8/26/20256.45 EUR
8/25/20256.70 EUR
8/22/20256.15 EUR
8/21/20256.75 EUR
8/20/20256.50 EUR
8/19/20255.10 EUR
8/18/20255.10 EUR
Access this data via the Eulerpool API
Get Free API Key

FamiCord Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
77.06 M EUR
-2.76 M EUR
-1.87 M EUR
Jan 1, 2024
82.18 M EUR
-9.26 M EUR
-12.14 M EUR
Jan 1, 2025
88.17 M EUR
-3.52 M EUR
-6.30 M EUR
Jan 1, 2026 (e)
85.00 M EUR
-11.52 M EUR
158,808.00 EUR
Jan 1, 2027 (e)
88.40 M EUR
-11.99 M EUR
952,848.00 EUR
Jan 1, 2028 (e)
91.90 M EUR
-12.46 M EUR
2.06 M EUR
Jan 1, 2029 (e)
89.93 M EUR
10.78 M EUR
0.00 EUR
Jan 1, 2030 (e)
92.58 M EUR
12.01 M EUR
0.00 EUR

FamiCord Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 18, 2026, 8:05 AM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
DIV.EUR
DIV. GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
14.0016.0019.0020.0020.0020.0028.0068.0077.0082.0088.0085.0088.0091.0089.0092.00
7.6914.2918.755.26––40.00142.8613.246.497.32-3.413.533.41-2.203.37
42.8650.0052.6355.0060.0055.0042.862.9436.3624.3950.0050.0050.0050.0050.0050.00
6.008.0010.0011.0012.0011.0012.002.0028.0020.0044.0042.5044.0045.5044.5046.00
1.00––2.003.002.00-2.00-26.00-2.00-9.00-3.00-11.00-11.00-12.0010.0012.00
7.14––10.0015.0010.00-7.14-38.24-2.60-10.98-3.41-12.94-12.50-13.1911.2413.04
1.00–––1.001.00-3.00-27.00-1.00-12.00-6.00––2.00––
––––––-400.00800.00-96.301,100.00-50.00–––––
0.150.160.160.160.16––––––0.160.170.17––
–6.67––––––––––6.25–––
2.823.575.074.194.264.0915.8315.8317.4314.4317.4317.4317.4317.4317.4317.43
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales FamiCord generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue FamiCord retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare FamiCord's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares FamiCord has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against FamiCord's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

FamiCord stock margins

The FamiCord margin analysis displays the gross margin, EBIT margin, as well as the profit margin of FamiCord. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for FamiCord.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
43.76 %
-10.12 %
-13.82 %
Jan 1, 2022
3.97 %
-38.78 %
-39.72 %
Jan 1, 2023
36.65 %
-3.58 %
-2.42 %
Jan 1, 2024
25.13 %
-11.26 %
-14.77 %
Jan 1, 2025
50.86 %
-3.99 %
-7.15 %
Jan 1, 2026 (e)
50.86 %
-13.56 %
0.19 %
Jan 1, 2027 (e)
50.86 %
-13.56 %
1.08 %
Jan 1, 2028 (e)
50.86 %
-13.56 %
2.25 %

FamiCord Stock Revenue, EBIT, Earnings per Share

The FamiCord earnings per share therefore indicates how much revenue FamiCord has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
1.80 EUR
-0.18 EUR
-0.25 EUR
Jan 1, 2022
4.36 EUR
-1.69 EUR
-1.73 EUR
Jan 1, 2023
4.42 EUR
-0.16 EUR
-0.11 EUR
Jan 1, 2024
5.70 EUR
-0.64 EUR
-0.84 EUR
Jan 1, 2025
5.06 EUR
-0.20 EUR
-0.36 EUR
Jan 1, 2026 (e)
5.35 EUR
-0.66 EUR
0.01 EUR
Jan 1, 2027 (e)
5.57 EUR
-0.69 EUR
0.06 EUR
Jan 1, 2028 (e)
5.79 EUR
-0.71 EUR
0.13 EUR

FamiCord business model & stock analysis

Vita 34 AG is a leading company in the field of stem cell technology. It was founded in Leipzig in 1997 and has since had an impressive history. The company focuses on the storage of stem cells from umbilical cord blood and umbilical cord tissue. These stem cells can be used later in life for the treatment of various diseases. The business model of Vita 34 AG involves customers storing and preserving their stem cells with them. The company offers various options to meet individual needs. Customers can choose between different packages that include different services. For example, a package can be booked that only includes the storage of umbilical cord blood, or another package that also includes the storage of umbilical cord tissue. In addition to stem cell storage, Vita 34 AG also offers various supplementary services. For example, customers can have genetic predisposition tests conducted to determine the risk for certain diseases. This allows customers to take targeted preventive measures and consider alternative treatment options if necessary. Another important aspect of Vita 34 AG's business is the trade of stem cells. By storing umbilical cord blood and tissue, the company builds an extensive portfolio of stem cells that can be sold to medical institutions when needed. The company works closely with doctors and research institutions to use the stem cells efficiently. Vita 34 AG operates not only in German-speaking countries but also has branches in other countries such as Austria, Switzerland, and the Netherlands. This allows the company to operate internationally and cater to the specific needs of individual countries. In addition to the mentioned services, Vita 34 AG also offers various products. For example, there are special storage kits for the storage of umbilical cord blood and tissue. Test kits for genetic predisposition tests can also be purchased. Vita 34 AG aims to increase awareness of stem cells and their therapeutic possibilities. Through intensive marketing, including in social networks, the company strives to ensure that as many people as possible learn about the benefits of stem cell technology and decide to store their stem cells with the company. Vita 34 AG has had an impressive development in recent years. It is now globally known and has established itself as a competent and reliable partner in the field of stem cell technology. With its wide range of services and products, it is often the first choice for many people when it comes to storing stem cells.

FamiCord SWOT Analysis

Strengths

Vita 34 AG is a leading company in the field of stem cell storage and regenerative medicine. It has a strong reputation and brand recognition, which gives it a competitive edge in the market.

The company has a well-established customer base and a wide network of partner hospitals and clinics.

Vita 34 AG possesses advanced technology and expertise in stem cell processing and cryopreservation, ensuring high-quality and reliable services.

Weaknesses

One of the weaknesses of Vita 34 AG is its dependency on regulatory approvals and governmental policies, which can impact its operations and market potential.

The company may face challenges related to customer education and awareness regarding the benefits and applications of stem cell storage.

Vita 34 AG's geographical presence is mainly concentrated in specific regions, limiting its market reach and growth opportunities.

Opportunities

The increasing acceptance of stem cell therapies and regenerative medicine presents an opportunity for Vita 34 AG to expand its services and customer base.

Collaboration with research institutions and healthcare providers can lead to the development of new treatments and further advancements in the field, benefiting Vita 34 AG.

International expansion and entering emerging markets with growing healthcare infrastructure can provide significant growth prospects for the company.

Threats

Competition from other stem cell banks and companies offering similar services is a major threat to Vita 34 AG's market share and profitability.

Changes in healthcare regulations and reimbursement policies can impact the demand for stem cell storage and affect the company's revenue streams.

Ethical and legal concerns surrounding stem cell research and usage may impose restrictions and limitations on Vita 34 AG's operations.

FamiCord Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

FamiCord historical P/E ratio, EBIT multiple, and P/S ratio

FamiCord annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

FamiCord shares outstanding

The number of shares of FamiCord was 17.43 M in 2025. This indicates how many shares FamiCord is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
15.83 M Stocks
Jan 1, 2022
15.83 M Stocks
Jan 1, 2023
17.43 M Stocks
Jan 1, 2024
14.43 M Stocks
Jan 1, 2025
17.43 M Stocks
Jan 1, 2026 (e)
17.43 M Stocks
Jan 1, 2027 (e)
17.43 M Stocks
Jan 1, 2028 (e)
17.43 M Stocks

FamiCord Dividend History

5 years of dividend payments

YearAnnual DividendYoY ChangePayments
20190.16EUR 0.0%1×
20180.16EUR 0.0%1×
20170.16EUR 0.0%1×
20160.16EUR↑ 6.7%1×
20150.15EUR—1×

FamiCord dividend payout ratio

In 2025, FamiCord had a payout ratio of 74.40%. The payout ratio indicates the percentage of the company's profits that FamiCord distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
73.53 %
Jan 1, 2022
71.08 %
Jan 1, 2023
77.94 %
Jan 1, 2024
74.18 %
Jan 1, 2025
74.40 %
Jan 1, 2026 (e)
1,637.48 %
Jan 1, 2027 (e)
279.31 %
Jan 1, 2028 (e)
131.93 %

Current FamiCord forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
0.00 % (0)
Hold
42.86 % (3)
Sell
57.14 % (4)
12M Price Target
7.65
Last Price
2.75
Currency
EUR
12M Return Potential
178.18 %
LTM Return
0 %

FamiCord Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
10/15/2007-0.02EUR-4.16 MEUR-2007 Q3

FamiCord shareholder structure

% Name
64.92520%
Schuhbauer (Florian)
Schuhbauer (Florian)
10.09700%
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A.
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A.
9.99703%
Shareholder Value Beteiligungen AG
Shareholder Value Beteiligungen AG

FamiCord Beneficial Ownership Filings (SEC 13D/G)

Free Float
31.6%
Float Shares
-
Shares Outstanding
-

FamiCord Executives and Management Board

9 members · avg. age 53 · 11 % women

JB

Mr. Jakub Baran

Chief Executive Officer, Member of the Management Board

436,973.00 EUR

Management

TB

Mr. Tomasz Baran

Member of the Management Board, Chief Commercial Officer

307,755.00 EUR
TP

Mr. Thomas Pfaadt

Chief Financial Officer, Member of the Management Board

168,409.00 EUR

Board of Directors

FS

Mr. Florian Schuhbauer (50)

Chairman of the Supervisory Board · since 2020

45,593.00 EUR
FK

Mr. Frank Koehler (61)

Independent Member of the Supervisory Board · since 2017

30,000.00 EUR
KM

Mr. Konrad Miterski (49)

Independent Member of the Supervisory Board

22,542.00 EUR
PO

Mr. Paul Owsianowski

Member of the Supervisory Board

22,242.00 EUR
US

Dr. Ursula Schuetze-Kreilkamp

Independent Member of the Supervisory Board

20,000.00 EUR
PG

Mr. Peter Greiner

Deputy Chairman of the Supervisory Board · since 2024

15,000.00 EUR

FamiCord Supply Chain

Frequently asked questions about FamiCord

Vita 34 AG's business model focuses on stem cell banking and regenerative medicine. As a biotechnology company, Vita 34 AG specializes in the collection, processing, and storage of stem cells derived from umbilical cord blood. By offering parents the opportunity to preserve their newborn's cord blood, Vita 34 AG contributes to potential future medical treatments and therapies. Through extensive quality control and state-of-the-art technologies, Vita 34 AG ensures the safe and professional handling of stem cells. With a strong emphasis on research and development, Vita 34 AG continues to advance its expertise in regenerative medicine, aiming to harness the potential of stem cells for various health-related applications.

Vita 34 AG is primarily active in the biotechnology and healthcare industries.

The main competitors of Vita 34 AG in the market include Cryo-Save AG, Cryo-Vita GmbH, StemCyte Inc., LifeCell International Pvt. Ltd, and Cordlife Group Limited.

Vita 34 AG is a German company that specializes in the field of stem cell banking. Established in 1997, Vita 34 is one of the oldest and largest stem cell banks in Europe. The company provides individuals the opportunity to store stem cells from umbilical cord blood and tissue which can be used in potential future medical treatments. Vita 34 AG's vision has always been to contribute to the development of innovative medical therapies and improve the quality of life for patients. With a strong focus on research and technological advancements, Vita 34 AG continues to be a leading player in the stem cell industry.

Vita 34 AG has achieved significant milestones in its history. It is noteworthy that the company pioneered the storage of umbilical cord blood as regenerative medicine in Europe. With over 20 years of experience, Vita 34 has established itself as a leading provider of stem cell banking services, offering secure and reliable storage options for families. The company has successfully expanded its operation to various countries, including Austria, Switzerland, and Brazil. Vita 34 AG continues to invest in research and development, ensuring cutting-edge technologies and future advancements in the field of stem cell preservation.

Vita 34 AG is primarily present in Germany, Austria, Switzerland, and other European countries.

Vita 34 AG is a leading biotech company that specializes in stem cell banking. The company's corporate philosophy is based on three core values: responsibility, innovation, and quality. Vita 34 AG is committed to taking responsibility for the long-term health preservation of individuals and their families by offering secure and reliable stem cell storage solutions. Through constant innovation, the company strives to stay at the forefront of stem cell technologies, ensuring the highest standards of quality and safety. Vita 34 AG believes in the immense potential of stem cells and their ability to revolutionize medical treatments, making them a trusted and forward-thinking partner in the field of regenerative medicine.

Analysts currently set an average price target of 7.65 EUR for the FamiCord stock (median: 7.65 EUR), implying +178.2 % versus the latest price. The consensus is based on 7 analyst ratings.

FamiCord Analyst Price Targets 2026

7 analysts currently rate the FamiCord stock: 0 recommend buying, 3 holding and 4 selling. For 2026, analysts expect FamiCord to generate revenue of 85.00 M EUR and earnings per share of 0.01 EUR.

FamiCord Analyst Price Targets 2026

The FamiCord share (V3V.DE) is listed on 8 stock exchanges, including: XETRA (V3V.DE), Frankfurt (V3V.F), München (V3V.MU), Düsseldorf (V3V.DU), Hamburg (V3V.HM), London (0NLV.L), SIX (Zürich) (V3V.SW).

The Vita 34 AG is a leading company in the field of stem cell storage for medical purposes. The company's business model includes various divisions to provide its customers with tailored solutions for stem cell storage. The main division of Vita 34 is the storage of stem cells for newborns. In this case, the company extracts valuable stem cells from the umbilical cord of the newborn during umbilical cord blood donation and stores them properly in a specially developed cryogenic storage system. These stem cells can be used later for the treatment of life-threatening diseases. Vita 34 also offers a storage solution for adults. With peripheral stem cell storage, stem cells can be taken from an adult's blood and stored. These stem cells can be effectively used for the treatment of diseases such as cancer and autoimmune diseases. Another division of the company is the sale of stem cell products. Vita 34 offers various products derived from the body's own stem cell material. This includes, among other things, the VitaPlus umbilical cord blood serum as a cosmetic product for skincare and the VitaMine&More dietary supplement. Both products contain important components from stem cells that support the body's immune system and promote well-being. In addition, Vita 34 offers a comprehensive service platform that supports customers with all questions related to stem cell therapy. This includes, among other things, consultations with medical experts and support in finding suitable therapy centers and methods. The business model of Vita 34 AG is strongly focused on customer orientation. The company offers its customers tailored solutions for stem cell storage as well as comprehensive consulting and service. This makes the company a worldwide leading provider of stem cell-based solutions for medical purposes.

The expected revenue of FamiCord is 85.00 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of FamiCord is 158,808.00 EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of FamiCord is currently 301.86. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the FamiCord stock.

The price-to-sales ratio (P/S) of FamiCord is currently 0.56. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the FamiCord stock.

The Eulerpool Quality Score for FamiCord is 3/10.

The ISIN of FamiCord is DE000A0BL849. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of FamiCord is A0BL84. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of FamiCord is V3V.DE. The ticker symbol is used to trade FamiCord shares on the stock exchange.

Over the past 12 months, FamiCord paid a dividend of 0.16 EUR . This corresponds to a dividend yield of about 5.82 %. For the coming 12 months, FamiCord is expected to pay a dividend of 0.17 EUR.

The current dividend yield of FamiCord is 5.82 %.

FamiCord pays a dividend, distributed in the months of , , , .

FamiCord paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 0.17 EUR are expected. This corresponds to a dividend yield of 6.09 %.

FamiCord is assigned to the 'Health' sector.

To receive the latest dividend of FamiCord from amounting to 0.16 EUR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

The dividends of FamiCord are distributed in EUR.

All fundamentals and in-depth analysis of FamiCord

Our stock analysis for FamiCord stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of FamiCord. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

FamiCord Stock
FamiCord Revenue→
FamiCord Stock
FamiCord Net Income→
FamiCord Stock
FamiCord P/E→
FamiCord Stock
FamiCord P/S→
FamiCord Stock
FamiCord EBIT→
FamiCord Stock
FamiCord Dividend→
FamiCord Stock
FamiCord Directors Dealings→
FamiCord Stock
FamiCord Stocks→
FamiCord Stock
FamiCord Market capitalization→
FamiCord Stock
FamiCord Debt→
FamiCord Stock
FamiCord Liabilities→
FamiCord Stock
FamiCord Equity→
FamiCord Stock
FamiCord AAQS→
FamiCord Stock
FamiCord Employees→
FamiCord Stock
FamiCord ROE→
FamiCord Stock
FamiCord ROA→
FamiCord Stock
FamiCord ROCE→
FamiCord Stock
FamiCord News→
FamiCord Stock
FamiCord Analyst Price Targets→

Health Stocks

Family Care HospitalsFalco Holdings CoFamon Awal Bros Sedaya Tbk PTFagronFaron Pharmaceuticals OyFaes FarmaFate TherapeuticsFabino EnterprisesFB Care Service CoF D CFeedbackEZZ Life Science HoldingsAll Stocks A–Z →